Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine.
The immunosuppression accompanying illicit drug use has been shown to contribute to a decreased resistance to a variety of pathogens; however, there is relatively little information on how long these effects persist following withdrawal from chronic drug exposure. To begin to address this question, Sprague-Dawley male rats were administered either cocaine (10 mg/kg, i.p., b.i.d.) for 7 days or morphine (escalating doses up to 40 mg/kg, s.c., b.i.d.) for a 10-day period. Control groups of animals received similar saline injections for equivalent time periods. Drug administration was abruptly discontinued and animals were sacrificed at 2, 24, 72 or 96 h following the last dose. At these time points, proliferation responses of peripheral blood T-lymphocytes stimulated by concanavalin A (Con A) and plasma levels of corticosterone were measured. Plasma corticosterone levels of cocaine- or morphine-treated animals were found to be significantly elevated 24 h following drug cessation as compared to saline animals. At this time, proliferation responses were significantly decreased and were further suppressed during cocaine and morphine withdrawal at 96 and 72 h, respectively. These results suggest that abrupt cessation of cocaine or morphine administration leads to activation of stress-related pathways that may contribute to an increased susceptibility of infection during the initial withdrawal phase.
Avila
Albert H
AH
Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20057, USA. avilaah@georgetown.edu
Alonzo
Norma C
NC
Bayer
Barbara M
BM
D000704:Analysis of Variance; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage / Q000009:adverse effects*; D003208:Concanavalin A / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008934:Mitogens / Q000494:pharmacology; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects*; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000276:immunology*; D013936:Thymidine / Q000097:blood; D013997:Time Factors; D014316:Tritium / Q000097:blood
D008934:Mitogens; D009294:Narcotics; D014316:Tritium; D003208:Concanavalin A; D009020:Morphine; D003042:Cocaine; D013936:Thymidine; D003345:Corticosterone